title: Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.
abstract: BACKGROUND
  Although a dramatic decrease in AIDS progression has been observed after Highly Active Anti Retroviral Therapy (HAART) in both low- and high-resource settings, few data support that fact in low-resource settings.This study describes the incidence of AIDS-defining illnesses (ADI) after HAART initiation and analyzes their risk factors in a low-resource setting. A focus was put on CD4 cell counts and viral load measurements.
  
  
  METHODS
  404 HIV-1-infected Senegalese adult patients were enrolled in a prospective observational cohort and data censored as of April 2008. A Poisson regression was used to model the incidence of ADIs over two periods and to assess its association with baseline variables, current CD4, current viral load, CD4 response, and virological response.
  
  
  RESULTS
  ADI incidence declined from 20.5 ADIs per 100 person-years, 95% CI = [16.3;25.8] during the first year to 4.3, 95% CI = [2.3;8.1] during the fourth year but increased afterwards. Before 42 months, the decrease was greater in patients with clinical stage CDC-C at baseline and with a viral load remaining below 1000 cp/mL but was uniform across CD4 strata (p = 0.1). After 42 months, 293 patients were still at risk. The current CD4 and viral load were associated with ADI incidence (decrease of 21% per 50 CD4/mm3 and of 61% for patients with a viral load < 1000 cp/mL).
  
  
  CONCLUSIONS
  During the first four years, a uniform decline of ADI incidence was observed even in patients with low CD4-cell counts at HAART initiation as long as the viral load remained undetectable. An increase was noted later in patients with immunologic and virological failures but also in patients with only virological failure.
authors.affiliation: Institut de Recherche pour le Développement (IRD), Université Montpellier 1, UMR 145, Montpellier, F-34000, France. pierre.debeaudrap@ird.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: De Beaudrap
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Etard
authors.forename: Assane
authors.initials: A
authors.lastname: Diouf
authors.forename: Ibrahima
authors.initials: I
authors.lastname: Ndiaye
authors.forename: Guèye Fatou N
authors.initials: GF
authors.lastname: Ndèye
authors.forename: Papa S
authors.initials: PS
authors.lastname: Sow
authors.forename: Kane Coumba T
authors.initials: KC
authors.lastname: Ndèye
authors.forename: René
authors.initials: R
authors.lastname: Ecochard
authors.forename: Eric
authors.initials: E
authors.lastname: Delaporte
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D015994:Incidence; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors; D012675:Senegal / Q000453:epidemiology; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents